Subtype
Lung Small Cell Carcinoma
CI-CAN-00005832SCLCExplore in graph →
381 active trials6 approved drugs6 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00005832SCLCExplore in graph →
Clinical trials
1,100 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (157)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06657222 | First in Human Study of TUB-030 in Patients With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 250 | Tubulis GmbHINDUSTRY | 5 | Sep 11, 2026 | clinicaltrials |
| NCT07161388 | Durvalumab Consolidation After Chemoradiation Therapy for Limited Stage SCLC in China(DREAM) | recruiting | — | 200 | AstraZenecaINDUSTRY | 1 | Sep 11, 2026 | clinicaltrials |
| NCT07564401 | A Study to Evaluate DJI136, a DLL3-targeted CAR-T Therapy | recruiting | Phase 1 / Phase 2 | 80 | Novartis PharmaceuticalsINDUSTRY | 4 | Sep 11, 2026 | clinicaltrials |
| NCT07815223 | A Phase II Study of Tislelizumab Plus Anlotinib Consolidation After Chemoradiotherapy in LS-SCLC | recruiting | Phase 2 | 20 | Yantai Yuhuangding HospitalOTHER | 1 | Sep 11, 2026 | clinicaltrials |
| NCT04514497 | Testing the Addition of an Anti-cancer Drug, BAY 1895344, to Usual Chemotherapy for Advanced Stage Solid Tumors, With a Specific Focus on Patients With Small Cell Lung Cancer, Poorly Differentiated Neuroendocrine Cancer, and Pancreatic Cancer | active not recruiting | Phase 1 | 29 | National Cancer Institute (NCI)NIH | 1 | Sep 10, 2026 | clinicaltrials |
| NCT05091567 | A Phase III, Open-Label Study of Maintenance Lurbinectedin in Combination With Atezolizumab Compared With Atezolizumab in Participants With Extensive-Stage Small-Cell Lung Cancer(IMforte) | active not recruiting | Phase 3 | 660 | Hoffmann-La RocheINDUSTRY | 13 | Sep 9, 2026 | clinicaltrials |
| NCT05361395 | First-Line Tarlatamab in Combination With Carboplatin, Etoposide, and PD-L1 Inhibitor in Subjects With Extensive Stage Small Cell Lung Cancer (ES-SCLC) | active not recruiting | Phase 1 | 184 | AmgenINDUSTRY | 15 | Sep 9, 2026 | clinicaltrials |
| NCT06780137 | A Study to Evaluate the Safety and Efficacy of Gocatamig (MK-6070) and Ifinatamab Deruxtecan (I-DXd) in Participants With Relapsed/Refractory Extensive-Stage Small Cell Lung Cancer (MK-6070-002) | recruiting | Phase 1 / Phase 2 | 327 | Merck Sharp & Dohme LLCINDUSTRY | 12 | Sep 9, 2026 | clinicaltrials |
| NCT07005128 | A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC)(DeLLphi-312) | active not recruiting | Phase 3 | 350 | AmgenINDUSTRY | 26 | Sep 8, 2026 | clinicaltrials |
| NCT07640932 | Lurbinectedin Plus Paclitaxel Versus Paclitaxel in Patients With Previously Treated Small Cell Lung Cancer(LUPINE) | not yet recruiting | Phase 2 | 69 | Yonsei UniversityOTHER | 1 | Sep 4, 2026 | clinicaltrials |
| NCT07803848 | Study to Confirm Efficacy and Feasibility of Tarlatamab Treatment in Patients With Extensive Stage Small-cell Lung Cancer With Poor Performance Status(SPACE-T) | recruiting | Phase 2 | 57 | AIO-Studien-gGmbHOTHER | 1 | Sep 4, 2026 | clinicaltrials |
| NCT04699838 | Chemo-Immunotherapy Followed by Durvalumab and Ceralasertib in Treatment Naïve Patients With Extensive Stage Small Cell Lung Cancer | active not recruiting | Phase 2 | 30 | Muhammad FurqanOTHER | 1 | Sep 3, 2026 | clinicaltrials |
| NCT07509333 | MDT-Based Umbrella Decision Model for Geriatric Lung Cancer Patients | recruiting | N/A | 2,000 | West China HospitalOTHER | 1 | Sep 3, 2026 | clinicaltrials |
| NCT07802821 | A Study Comparing QLC5508 in Combination With QL2107 Versus Tislelizumab Plus Platinum-based Chemotherapy in Participants Wih Treatment-naïve Extensive-Stage Small Cell Lung Cancer | not yet recruiting | Phase 3 | 556 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 0 | Sep 3, 2026 | clinicaltrials |
| NCT07783477 | A Study of Armored CAR T Cells in People With Cancer | recruiting | Phase 1 | 16 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Sep 2, 2026 | clinicaltrials |
| NCT07798947 | A Phase II Clinical Study of SHR-7787 Injection Combined With SHR-1316 Injection in Patients With LS-SCLC | not yet recruiting | Phase 2 | 120 | Shanghai Hengrui Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 2, 2026 | clinicaltrials |
| NCT06712355 | Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer | recruiting | Phase 3 | 621 | BioNTech SEINDUSTRY | 14 | Sep 1, 2026 | clinicaltrials |
| NCT07795411 | Prospective Multiomic Analysis in Small-Cell Lung Cancer | not yet recruiting | — | 30 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Aug 31, 2026 | clinicaltrials |
| NCT07796100 | A Study of ZL-1310 in Combination With a Checkpoint Inhibitor Versus Standard of Care Platinum Based Chemotherapy With a Checkpoint Inhibitor as First-line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer | not yet recruiting | Phase 3 | 530 | Zai Lab (Shanghai) Co., Ltd.INDUSTRY | 0 | Aug 31, 2026 | clinicaltrials |
| NCT07057791 | Phase II Study of Platinum/Etoposide Plus Ivonescimab for Extensive-Stage Small Cell Lung Cancer(PrE0510) | recruiting | Phase 2 | 60 | PrECOG, LLC.OTHER | 1 | Aug 28, 2026 | clinicaltrials |
| NCT01064466 | Pharmacogenomics ANDA SNP Clinical Study - Etoposide and Single Nucleotide Polymorphisms(Drugs-SNPs) | active not recruiting | Phase 2 / Phase 3 | 600 | Han Xu, M.D., Ph.D., FAPCR, Medical Director,, IRB ChairINDUSTRY | 1 | Aug 27, 2026 | clinicaltrials |
| NCT03811002 | Testing the Addition of a New Immunotherapy Drug, Atezolizumab (MPDL3280A), to the Usual Chemoradiation (CRT) Therapy Treatment for Limited Stage Small Cell Lung Cancer (LS-SCLC) | active not recruiting | Phase 3 | 544 | National Cancer Institute (NCI)NIH | 2 | Aug 27, 2026 | clinicaltrials |
| NCT05924841 | A Study of BL-B01D1, SI-B003 and BL-B01D1+SI-B003 in Patients With Extensive Stage Small Cell Lung Cancer | recruiting | Phase 2 | 100 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Aug 27, 2026 | clinicaltrials |
| NCT06726148 | Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and in Patients With Other Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 280 | Novartis PharmaceuticalsINDUSTRY | 16 | Aug 27, 2026 | clinicaltrials |
| NCT07488923 | A First-in-human (FIH), Phase 1 Study of ML261, an Autologous Potency Enhanced Anti-DLL3 CAR T Cell Therapy, in Participants With R/R SCLC or Select NECs (SPECTRAL-1) | recruiting | Phase 1 | 110 | Moonlight Bio, IncINDUSTRY | 1 | Aug 25, 2026 | clinicaltrials |
| NCT07654400 | A Study of BL-M14D1 in Combination With Atezolizumab in Patients With Extensive-stage Small Cell Lung Cancer | recruiting | Phase 2 | 36 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Aug 25, 2026 | clinicaltrials |
| NCT07739758 | A Study of YL201 in Combination With Serplulimab in Participants With Treatment-naïve Extensive-stage Small Cell Lung Cancer | recruiting | Phase 3 | 442 | MediLink Therapeutics (Suzhou) Co., Ltd.INDUSTRY | 1 | Aug 24, 2026 | clinicaltrials |
| NCT05963867 | A Study to Test How BI 764532 is Taken up by Tumours in People With Small-cell Lung Cancer or Neuroendocrine Cancer | recruiting | Phase 1 | 12 | Boehringer IngelheimINDUSTRY | 1 | Aug 21, 2026 | clinicaltrials |
| NCT06179069 | A Study of ZL-1310 in Subjects With Small Cell Lung Cancer | recruiting | Phase 1 | 339 | Zai Lab (Shanghai) Co., Ltd.INDUSTRY | 3 | Aug 21, 2026 | clinicaltrials |
| NCT07531095 | Study of Tarlatamab + ZL-1310 +/- Anti-programmed Death Ligand 1 (Anti-PD-L1) in Small Cell Lung Cancer (SCLC)(DeLLphi-313) | recruiting | Phase 1 | 160 | AmgenINDUSTRY | 9 | Aug 21, 2026 | clinicaltrials |
| NCT07623369 | A First-in-Human Study of HH160 in Participants With Advanced or Metastatic Solid Tumors | recruiting | Phase 1 | 299 | Huahui HealthINDUSTRY | 2 | Aug 21, 2026 | clinicaltrials |
| NCT05142696 | A Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed ES-SCLC Patients in Combination With Carboplatin, Etoposide and Atezolizumab | active not recruiting | Phase 1 / Phase 2 | 55 | Novartis PharmaceuticalsINDUSTRY | 12 | Aug 19, 2026 | clinicaltrials |
| NCT06922539 | Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/ Refractory Small Cell Lung Cancer | recruiting | Phase 1 | 44 | SciTech Development, Inc.INDUSTRY | 1 | Aug 19, 2026 | clinicaltrials |
| NCT06095505 | A Study of Alisertib in Patients With Extensive Stage Small Cell Lung Cancer(ALISCA-Lung1) | recruiting | Phase 2 | 120 | Puma Biotechnology, Inc.INDUSTRY | 1 | Aug 17, 2026 | clinicaltrials |
| NCT06745323 | A Phase 2, Open-label, Randomized, Multicenter Study of Tarlatamab Dosing Regimens in Subjects With SCLC(DeLLphi-309) | active not recruiting | Phase 2 | 252 | AmgenINDUSTRY | 16 | Aug 17, 2026 | clinicaltrials |
| NCT06768307 | Assessment of Adebelizumab Combined With Chemotherapy in Concurrent Radiotherapy Versus Sequential Radiotherapy as First-Line Treatment for Extensive-Stage Small Cell Lung Cancer | recruiting | Phase 2 | 60 | Peking University Cancer Hospital & InstituteOTHER | 1 | Aug 17, 2026 | clinicaltrials |
| NCT02688894 | The Molecular Screening Study for the Umbrella Trial (SUKSES) in Relapsed Small Cell Lung Cancer Patients [SUKSES-S] | recruiting | — | 797 | Samsung Medical CenterOTHER | 1 | Aug 12, 2026 | clinicaltrials |
| NCT04199741 | PET/CT Imaging of Small Cell Lung Cancer Using 89Zr-DFO-SC16.56 | recruiting | Phase 1 / Phase 2 | 105 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Aug 12, 2026 | clinicaltrials |
| NCT05552846 | Phase II Trial of Consolidative Thoracic Radiotherapy for ES-SCLC After Standard Care of Chemo-immunotherapy | recruiting | N/A | 104 | Ruijin HospitalOTHER | 1 | Aug 12, 2026 | clinicaltrials |
| NCT06801834 | Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer(EVOKE-SCLC-04) | recruiting | Phase 3 | 695 | Gilead SciencesINDUSTRY | 23 | Aug 12, 2026 | clinicaltrials |
| NCT07155200 | Small Cell Lung Cancer Irinotecan and CDC2-like Kinase Inhibition Trial (SLICK Trial) | recruiting | Phase 1 / Phase 2 | 42 | Washington University School of MedicineOTHER | 1 | Aug 12, 2026 | clinicaltrials |
| NCT07759856 | NK Cells Plus ICI for SCLC Maintenance(NK-ICI-SCLC) | recruiting | Phase 2 | 42 | Tianjin First Central HospitalOTHER | 1 | Aug 12, 2026 | clinicaltrials |
| NCT06242470 | A Study of MGC026 in Participants With Advanced Solid Tumors | recruiting | Phase 1 | 250 | MacroGenicsINDUSTRY | 3 | Aug 11, 2026 | clinicaltrials |
| NCT06807632 | A Study of Valemetostat in Combination With Atezolizumab in People With Lung Cancer | recruiting | Phase 1 | 24 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Aug 11, 2026 | clinicaltrials |
| NCT07752875 | A Study of LG00313112 in Participants With Advanced Solid Malignancies Harboring a TP53 Y220C Mutation | not yet recruiting | Phase 1 / Phase 2 | 250 | LG ChemINDUSTRY | 0 | Aug 7, 2026 | clinicaltrials |
| NCT06203210 | A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer(IDeate-Lung02) | recruiting | Phase 3 | 540 | Daiichi SankyoINDUSTRY | 23 | Aug 6, 2026 | clinicaltrials |
| NCT07468656 | SCLC Tarlatamab Blood Collection | not yet recruiting | — | 25 | Duke UniversityOTHER | 0 | Aug 5, 2026 | clinicaltrials |
| NCT05879978 | A Study to Test How Well Different Doses of Obrixtamig (BI 764532) in Combination With Ezabenlimab Are Tolerated by People With Small Cell Lung Cancer and Other Neuroendocrine Tumours That Are Positive for DLL3 | active not recruiting | Phase 1 | 45 | Boehringer IngelheimINDUSTRY | 4 | Aug 4, 2026 | clinicaltrials |
| NCT06486428 | Small Cell Lung Cancer Community Engagement to Eliminate Research Discepancies(SUCCEED) | active not recruiting | — | 22 | Addario Lung Cancer Medical InstituteOTHER | 1 | Aug 4, 2026 | clinicaltrials |
Data updated 19 days agoSource updated Sep 11, 2026source: clinicaltrials